Unitaid Provides $30M to Lower Cost of Cepheid TB Test in Developing World | GenomeWeb

NEW YORK (GenomeWeb News) – Global non-profit health advocacy organization Unitaid said today that its board has approved $30 million in funding to increase access to Cepheid's Xpert MTB/RIF diagnostic test for multi-drug-resistant tuberculosis in resource-poor areas of the world.

Under the agreement between Unitaid, the US Agency for International Development, and the Bill & Melinda Gates Foundation, Cepheid is expected to reduce the price of its Xpert MTB/RIF diagnostic cartridges to $10 from the current compassionate pricing of approximately $17, Unitaid said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Being born premature shouldn't mean infants with high blood sugar levels don't undergo genetic testing for neonatal diabetes, a study in Pediatrics says.

In Cell this week: phosphoproteomic patterns in prostate cancer, effect of gene expression on fitness in yeast, and more.

Scripps Research Institute investigators peer back at the RNA world.

In PNAS this week: chromosome instability in S. cerevisiae, structural differences and sequence divergence in rice, and more.